Validating Direct Oral Anticoagulants (DOACs) for Use in Children by the Throm-PED DOAC Registry of the International Pediatric Thrombosis Network

Susanne Holzhauer, M.D.
Charité University Medicine
Berlin, Germany

Treatment of pediatric venous thromboembolism has been revolutionized with approval of dabigatran and rivaroxaban. Susanne Holzhauer, M.D., presents the efficacy and safety of direct oral anticoagulants in a large, heterogenous pediatric population for children across different risk profiles. Discussion of a multicenter prospective observational cohort focused on outcomes of thrombus progression/recurrence and bleeding. Importance of real-world data collection to assist with patient identification for dose adjustments of groups that are at risk of worse outcomes is discussed.

Previous Article JTH Journal Editors Tout Rising Impact Factor
Next Article Arterial Thromboembolism Risk Assessment Model in Hospitalized COVID-19 Patients